Drug introduction and main uses of Fostamatinib

Fostamatinib is an oral small molecule drug that is a spleen tyrosine kinase (Syk) inhibitor. It mainly inhibits the Syk pathway and reduces the attack of immune cells on antibody-labeled cells, thereby regulating the immune response. Its active metabolite is R406, which has a clear immunomodulatory effect, so fostatinib is classified as a new immunotherapy drug.

Fostatinib was initially approved by the USFDA for the treatment of chronic immune thrombocytopenia (ITP), and is suitable for adult patients who have failed to respond to previous treatments (such as glucocorticoids, immunoglobulins, etc.). ITP is a bleeding disorder caused by excessive platelet destruction caused by immune system abnormalities. Fostatinib effectively reduces antibody-mediated platelet clearance by inhibiting Syk signaling, thereby increasing the patient's platelet level.

In addition to treating ITP, fostatinib is also being studied in other autoimmune diseases, such as rheumatoid arthritis, IgA nephropathy and autoimmune hemolytic anemia. In these diseases, the Syk pathway also plays a key role, so fostatinib, as a promising immunomodulatory drug, has the potential to further expand its indications.

Fostatinib is usually administered in the form of oral tablets, and the dosage needs to be adjusted based on the patient's specific condition and physician guidance. Blood pressure, liver function and hematological indicators need to be monitored regularly during use to ensure the safety and efficacy of the drug. At present, fostatinib is not widely available in China, and some patients need to obtain the drug from overseas channels. Therefore, they should fully understand its indications, possible side effects and precautions before use.

Reference materials:https://go.drugbank.com/drugs/DB12010